Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
Ilmatinib is currently the most widely used tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML) in Russia. When patients develop resistance or intolerance to imatinib, second generation tyrosine kinase inhibitors (Tkis) are used. in Russia, nilotinib, dasatinib and bosutini...
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Artikel |
| Taal: | Russian |
| Gepubliceerd in: |
IRBIS LLC
2018-08-01
|
| Reeks: | Фармакоэкономика |
| Onderwerpen: | |
| Online toegang: | https://www.pharmacoeconomics.ru/jour/article/view/248 |